Making use of autologous pericardium when options, and reconstruction references, are few
There are no easy solutions for acute infective tricuspid valve endocarditis in IV drug users, as the risk of prosthetic endocarditis in this population is high. Complete valve resection without replacement is feasible but leads to progressive right-sided heart failure. Reconstruction of the tricuspid valve with autologous pericardium is an alternative option, as demonstrated in the video case study below.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
A 29-year-old female drug abuser with fever, hemoptysis and MRSA bacteremia was started on IV antibiotics. She looked frail and had prominent jugular venous pressure as well as 95 percent saturation on 2 liters of nasal cannula oxygen. She was not on inotropes and had a pulmonary artery pressure of 40/20 mmHg with a good cardiac index. Chest CT showed a large left pleural effusion with associated atelectasis of the left lung. The right lung had manifestations of septic emboli and a smaller pleural effusion.
A Cleveland Clinic surgical team led by cardiothoracic surgeon Faisal Bakaeen, MD, proceeded to excise the patient’s extensive infected and devitalized tissue around the tricuspid valve, leaving only a portion of the anterior leaflet to serve as a reference for reconstruction using autologous pericardium. Dr. Bakaeen walks us through the essential surgical steps — and their underlying rationale — in the narrated operative video below.
Advertisement
Advertisement
End-of-treatment VALOR-HCM analyses reassure on use in women, suggest disease-modifying potential
New Cleveland Clinic data challenge traditional size thresholds for surgical intervention
3 specialists share multidisciplinary perspectives on a widely impactful cardiovascular condition
Experience-based takes on valve-sparing root replacement from two expert surgeons
Two surgeons share insights on weighing considerations across the lifespan
Join us in Florida this winter for a long-standing CME favorite
BITA grafts themselves are rarely to blame, and outcomes can be good
First-in-human phase 1 trial induced loss of function in gene that codes for ANGPTL3